Results: Longitudinal Therapy Study of Mice Bearing Subcutaneous SW1222 Tumors
9:00
Conclusion
Transkript
This protocol describes how to apply a pretargeted methodology to the targeted radiotherapy of cancer xenographs in the mouse model. Pretargeted radioimmunotherapy or PRIT allows us to inject the antibody and radioligand separately, and let the tw
Melden Sie sich an oder starten Sie Ihre kostenlose Testversion, um auf diese Inhalt zuzugreifen
This protocol describes the synthesis and characterization of a trans-cyclooctene (TCO)-modified antibody and a 177Lu-labeled tetrazine (Tz) radioligand for pretargeted radioimmunotherapy (PRIT). In addition, it details the use of these two constructs for in vivo biodistribution and longitudinal therapy studies in a murine model of colorectal cancer.